These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 15812265

  • 1. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T, Fukuda K, Azuma J, Kinoshita T.
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
    Murphy GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF.
    Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.
    Ushiroyama T, Ikeda A, Ueki M.
    J Med; 2004 Nov; 35(1-6):151-62. PubMed ID: 18084873
    [Abstract] [Full Text] [Related]

  • 5. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression.
    Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ.
    Neuropsychopharmacology; 2000 Nov; 23(5):587-90. PubMed ID: 11027924
    [Abstract] [Full Text] [Related]

  • 6. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders.
    Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R.
    Am J Med Genet B Neuropsychiatr Genet; 2004 Aug 15; 129B(1):36-40. PubMed ID: 15274037
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
    Mundo E, Bianchi L, Bellodi L.
    J Clin Psychopharmacol; 1997 Aug 15; 17(4):267-71. PubMed ID: 9241005
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.
    Kato M, Wakeno M, Okugawa G, Fukuda T, Takekita Y, Hosoi Y, Azuma J, Kinoshita T, Serretti A.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May 15; 32(4):1041-4. PubMed ID: 18325652
    [Abstract] [Full Text] [Related]

  • 13. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
    Stahl SM, Entsuah R, Rudolph RL.
    Biol Psychiatry; 2002 Dec 15; 52(12):1166-74. PubMed ID: 12488062
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S, Arita S.
    Eur Psychiatry; 2003 Dec 15; 18(8):418-20. PubMed ID: 14680720
    [No Abstract] [Full Text] [Related]

  • 16. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin.
    Arias B, Serretti A, Lorenzi C, Gastó C, Catalán R, Fañanás L.
    J Affect Disord; 2006 Feb 15; 90(2-3):251-6. PubMed ID: 16356553
    [Abstract] [Full Text] [Related]

  • 17. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review.
    Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH.
    Mol Psychiatry; 2004 May 15; 9(5):433-41. PubMed ID: 15037864
    [Abstract] [Full Text] [Related]

  • 18. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder.
    Ruhé HG, Ooteman W, Booij J, Michel MC, Moeton M, Baas F, Schene AH.
    Pharmacogenet Genomics; 2009 Jan 15; 19(1):67-76. PubMed ID: 18987562
    [Abstract] [Full Text] [Related]

  • 19. 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients.
    Kato M, Zanardi R, Rossini D, De Ronchi D, Okugawa G, Kinoshita T, Colombo C, Serretti A.
    Psychiatry Res; 2009 May 15; 167(1-2):97-105. PubMed ID: 19361869
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.